KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Other Non-Current Assets (2017 - 2025)

Novartis Ag's Other Non-Current Assets history spans 7 years, with the latest figure at $509.0 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 20.62% year-over-year to $509.0 million; the TTM value through Dec 2025 reached $509.0 million, up 20.62%, while the annual FY2025 figure was $509.0 million, 20.62% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $509.0 million at Novartis Ag, up from $422.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.2 billion in Q4 2021 and bottomed at $422.0 million in Q4 2024.
  • The 4-year median for Other Non-Current Assets is $854.0 million (2023), against an average of $1.1 billion.
  • The largest annual shift saw Other Non-Current Assets crashed 64.8% in 2024 before it rose 20.62% in 2025.
  • A 4-year view of Other Non-Current Assets shows it stood at $2.2 billion in 2021, then crashed by 45.75% to $1.2 billion in 2023, then plummeted by 64.8% to $422.0 million in 2024, then grew by 20.62% to $509.0 million in 2025.
  • Per Business Quant, the three most recent readings for NVS's Other Non-Current Assets are $509.0 million (Q4 2025), $422.0 million (Q4 2024), and $1.2 billion (Q4 2023).